

AMENDMENTS TO THE CLAIMS

The claims in this listing will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-12. (Canceled)

Claim 13. (Previously Presented) An isolated porcine uroplakin II gene promoter having the base sequence of SEQ ID NO: 1.

Claim 14. (Canceled)

Claim 15. (Previously Presented) An expression vector comprising the base sequence of the promoter of Claim 13 and a base sequence coding for a target protein at the 3' end of the promoter.

Claim 16. (Canceled)

Claim 17. (Previously Presented) The expression vector of Claim 15, wherein the target protein is human erythropoietin (EPO).

Claim 18. (Canceled)

Claim 19. (Previously Presented) The expression vector of Claim 17, which is the expression vector pUP2/hEPO deposited under the accession number KCTC 10352BP.

Claim 20. (Previously Presented) The expression vector of Claim 17, which is an I/pUP2/hEPO vector containing the neomycin-resistant gene of SEQ ID NO: 5 as a selective marker, and the insulator of SEQ ID NO: 6 at the 5' end of the UPII promoter.

Claim 21. (Canceled)

Claim 22. (Previously Presented) The expression vector of Claim 17, which is a pUP2/hEPO (WPRES) vector containing the neomycin-resistant gene of SEQ ID NO: 5 as a selective marker, and the woodchuck hepatitis virus posttranscriptional regulatory element (WPRES) of SEQ ID NO: 7 at the 3' end of the EPO gene.

Claim 23. (Canceled)

Claim 24. (Previously Presented) The expression vector of Claim 17, which is an I/pUP2/hEPO (WPRES) vector that contains the neomycin-resistant gene of SEQ ID NO: 5 as a selective marker, the insulator of SEQ ID NO: 6 at the 5' end of the UP2 promoter, and an WPRES of SEQ ID NO: 7 at the 3'-end of the EPO gene.

Claim 25. (Canceled)

Claim 26. (Currently Amended) ~~An animal's~~ A mouse's fertilized ovum introduced with the expression vector of Claim 17.

Claim 27. (Canceled)

Claim 28. (Currently Amended) ~~An animal's~~ A mouse's fertilized ovum introduced with the expression vector of Claim 19.

Claim 29. (Currently Amended) ~~An animal's~~ A mouse's fertilized ovum introduced with the expression vector of Claim 20.

Claim 30. (Canceled)

Claim 31. (Currently Amended) ~~An animal's~~ A mouse's fertilized ovum introduced with the expression vector of Claim 22.

Claim 32. (Canceled)

Claim 33. (Currently Amended) ~~An animal's~~ A mouse's fertilized ovum introduced with the expression vector of Claim 24.

Claim 34. (Canceled)

Claim 35. (Currently Amended) A transgenic ~~animal~~ mouse obtained by the implantation of the fertilized ovum of Claim 26.

Claim 36. (Canceled)

Claim 37. (Currently Amended) A transgenic ~~animal~~ mouse obtained by the implantation of the fertilized ovum of Claim 28.

Claim 38. (Currently Amended) A transgenic ~~animal~~ mouse obtained by the implantation of the fertilized ovum of Claim 29.

Claim 39. (Canceled)

Claim 40. (Currently Amended) A transgenic ~~animal~~ mouse obtained by the implantation of the fertilized ovum of Claim 31.

Claim 41. (Canceled)

Claim 42. (Currently Amended) A transgenic ~~animal~~ mouse obtained by the implantation of the fertilized ovum of Claim 33.

Claim 43-52 (Canceled)

Claim 53. (Currently Amended) A method for producing ~~useful proteins~~ erythropoietin (EPO), which comprises the steps of:

implanting ~~the animal's~~ a mouse's fertilized ovum introduced with the expression vector of Claim 17 into a surrogate mother ~~animal~~ mouse; and

obtaining transgenic ~~animals~~ mice from the surrogate mother ~~animal~~ mouse; and

isolating and purifying ~~useful proteins~~ EPO from the urine of at least one of the transgenic ~~animals~~ mice.

Claim 54. (Canceled)

Claim 55. (Currently Amended) A method for producing ~~useful proteins~~ erythropoietin (EPO), which comprises the steps of:

implanting ~~the animal's~~ a mouse's fertilized ovum introduced with the expression vector of Claim 19 into a surrogate mother ~~animal~~ mouse; and

obtaining transgenic ~~animals~~ mice from the surrogate mother ~~animal~~ mouse; and

isolating and purifying ~~useful proteins~~ EPO from the urine of at least one of the transgenic ~~animals~~ mice.

Claim 56. (Currently Amended) A method for producing ~~useful proteins~~ erythropoietin (EPO), which comprises the steps of:

implanting ~~the animal's~~ a mouse's fertilized ovum introduced with the expression vector of Claim 20 into a surrogate mother ~~animal~~ mouse; and

obtaining transgenic ~~animals~~ mice from the surrogate mother ~~animal~~ mouse; and

isolating and purifying ~~useful proteins~~ EPO from the urine of at least one of the transgenic ~~animals~~ mice.

Claim 57. (Canceled)

Claim 58. (Currently Amended) A method for producing ~~useful proteins~~ erythropoietin (EPO), which comprises the steps of:

implanting ~~the animal's~~ a mouse's fertilized ovum introduced with the expression vector of Claim 22 into a surrogate mother ~~animal~~ mouse; and

obtaining transgenic ~~animals~~ mice from the surrogate mother ~~animal~~ mouse; and

isolating and purifying ~~useful proteins~~ EPO from the urine of at least one of the transgenic animals.

Claim 59. (Canceled)

Claim 60. (Currently Amended) A method for producing ~~useful proteins~~ erythropoietin (EPO), which comprises the steps of:

implanting ~~the animal's~~ a mouse's fertilized ovum introduced with the expression vector of Claim 24 into a surrogate mother ~~animal~~ mouse; and

obtaining transgenic ~~animals~~ mice from the surrogate mother ~~animal~~ mouse; and

isolating and purifying ~~useful proteins~~ EPO from the urine of at least one of the transgenic ~~animals~~ mice.

Claim 61. (Canceled)